 |
| 19-Apr-13 | Reiterated |
UBS |
Buy |
$40 → $42 |
|
| 19-Apr-13 | Reiterated |
Mizuho |
Buy |
$37 → $42 |
|
| 25-Jan-13 | Reiterated |
UBS |
Buy |
$43 → $40 |
|
| 16-Nov-12 | Initiated |
Mizuho |
Buy |
$37 |
|
| 19-Oct-12 | Reiterated |
ISI Group |
Sell |
$30.50 → $29 |
|
| 27-Sep-12 | Reiterated |
ISI Group |
Sell |
$35 → $32.50 |
|
| 30-Aug-12 | Initiated |
Cantor Fitzgerald |
Hold |
$40 |
|
| 14-May-12 | Downgrade |
GARP Research |
Buy → Neutral |
|
|
| 06-Jan-12 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$38 → $42 |
|
| 11-Oct-11 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$30 → $38 |
|
| 22-Jul-11 | Reiterated |
Oppenheimer |
Outperform |
$33 → $38 |
|
| 14-Jul-11 | Reiterated |
Canaccord Genuity |
Buy |
$36 → $40 |
|
| 17-Mar-11 | Initiated |
Oppenheimer |
Outperform |
$33 |
|
| 28-Jan-11 | Reiterated |
Wedbush |
Neutral |
$23 → $25 |
|
| 28-Jan-11 | Reiterated |
RBC Capital Mkts |
Sector Perform |
$20 → $22 |
|
| 14-Dec-10 | Downgrade |
Wedbush |
Outperform → Neutral |
$22 → $23 |
|
| 09-Dec-10 | Reiterated |
UBS |
Neutral |
$22 → $26 |
|
| 16-Nov-10 | Initiated |
Canaccord Genuity |
Buy |
$27 |
|
| 21-May-10 | Initiated |
GARP Research |
Buy |
|
|
| 23-Apr-10 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$16 → $24 |
|
|
|
| 15-May-13 12:00AM | Primecap Rides Health to Top Growth Fund: Riskless Return at Bloomberg |
| 13-May-13 02:20PM | Neutral Rating Restated for Cepheid Zacks |
| 10-May-13 01:04PM | CEPHEID Financials EDGAR Online Financials |
| 07-May-13 04:05PM | Cepheid Welcomes Executive Vice President of Global Operations PR Newswire |
| 09:16AM | CEPHEID Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Fi EDGAR Online |
| 02-May-13 01:40PM | DexCom Loss Narrower than Est. Zacks |
| 10:31AM | CEPHEID Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online |
| 09:08AM | CEPHEID Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 01-May-13 04:05PM | Cepheid to Webcast Upcoming Financial Presentations PR Newswire |
| 29-Apr-13 01:40PM | ResMed's Earnings Beat; Revs Lag Zacks |
| 26-Apr-13 12:50PM | FDA Taking More Aggressive Approach in Areas of Totally Unmet Medical Need, Granting Breakthrough Status to New Drugs in Development if No Other Therapeutic Option Wall Street Transcript |
| 24-Apr-13 09:13AM | Target Executive Officer Sells More Than 41K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet |
| 21-Apr-13 01:46PM | Did These Stocks Miss or Beat Analyst Expectations? at Wall St. Cheat Sheet |
| 19-Apr-13 02:20PM | Covidien Expands Shiley Offerings Zacks +5.40% |
| 01:40PM | FDA Nod for Luminex Offering Zacks |
| 10:50AM | Cepheid Earnings Beat, Retains Outlook Zacks |
| 08:45AM | Cepheid should be bought into strength, says RW Baird at theflyonthewall.com |
| 18-Apr-13 09:20PM | Cepheid Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 06:34PM | Cepheid posts 1Q profit as sales improve AP |
| 05:19PM | Cepheid Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet |
| 04:08PM | InPlay: Cepheid beats by $0.01, beats on revs; guides FY13 EPS in-line, revs in-line Briefing.com |
| 04:05PM | Cepheid Reports 2013 First Quarter Results PR Newswire |
| 03:10PM | New Patent for Biolase Zacks |
| 02:30PM | Myriad Downgraded to Neutral Zacks |
| 02:20PM | Volcano Corporation Stays Neutral Zacks |
| 01:40PM | Encouraging 4Q Prelims for Abiomed Zacks |
| 09:16AM | CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 07:07AM | Q1 2013 Cepheid Earnings Release - After Market Close CCBN |
| 17-Apr-13 06:35PM | AK Steel to Lift up Steel Prices Zacks |
| 02:35PM | More Backing for HOLX Tomosynthesis Zacks |
| 02:15PM | Varian Applies Latest Vitesse Zacks |
| 12:20PM | Another Earnings Miss for DGX Zacks |
| 16-Apr-13 05:10PM | Covance Augments Singapore Facility Zacks |
| 15-Apr-13 03:50PM | Biolase Gets FDA Nod for EPIC 10S Zacks |
| 02:20PM | BSX Precision System Now in U.S. Zacks |
| 12-Apr-13 01:50PM | Cyberonics Stands Out at Outperform Zacks |
| 01:40PM | Thoratec Upgraded to Neutral Zacks |
| 08:30AM | FDA Approves TFX's ISO-Gard Mask Zacks |
| 11-Apr-13 02:10PM | Product Recall Plagues Integra Zacks |
| 10-Apr-13 04:31PM | BioScrip Raised to Outperform Zacks |
| 02:20PM | Merge Enhances eClinical OS Platform Zacks |
| 09-Apr-13 01:50PM | Safeway's Blackhawk Settles IPO Price Zacks |
| 12:36PM | [video] Chinas Slowing Inflation Is Good News for Asia at MarketWatch |
| 12:35PM | [video] Chinas Slowing Inflation Is Good News for Asia at MarketWatch |
| 08:10AM | ANGO Posts Dismal 3Q Earnings Zacks |
| 12:02AM | [video] Chinas Slowing Inflation Is Good News for Asia at MarketWatch |
| 08-Apr-13 02:30PM | CYBX Resumes Reimbursement Efforts Zacks |
| 01:50PM | Hologic Reiterated at Neutral Zacks |
| 05-Apr-13 01:48PM | Milestone for Accuray TomoTherapy Zacks |
| 01:38PM | Still Neutral on Merge Healthcare Zacks |
| 04-Apr-13 04:05PM | Cepheid Schedules 2013 First Quarter Results Announcement And Webcast PR Newswire |
| 01:38PM | Mindray to Exhibit at CMEF Zacks |
| 03-Apr-13 08:08AM | Abiomed Begins Impella RP Trial Zacks |
| 02-Apr-13 01:48PM | ResMed Protects Patent Landscape Zacks |
| 28-Mar-13 04:46PM | Cepheid Larger Than S&P 500 Component First Solar at Forbes |
| 06-Mar-13 01:04PM | CEPHEID Financials EDGAR Online Financials |
| 05-Mar-13 11:41AM | Luminex Has Both Many Opportunities And Many Questions To Answer at Seeking Alpha |
| 28-Feb-13 04:10PM | CEPHEID Files SEC form 10-K, Annual Report EDGAR Online |
| 25-Feb-13 11:56AM | 9.1% of TB Drugs Fail Quality Control at Motley Fool |
| 21-Feb-13 01:48PM | Collaborative Research for Cepheid Zacks |
| 19-Feb-13 04:57PM | Cepheid plans breast and prostate cancer test AP |
| 04:06PM | InPlay: Cepheid and Oregon Health & Science University collaborate to develop Oncology Assays for GeneXpert System Briefing.com |
| 04:05PM | Cepheid And Oregon Health & Science University Collaborate To Develop Oncology Assays For GeneXpert® System PR Newswire |
| 14-Feb-13 04:22PM | CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04:07PM | InPlay: Cepheid announces its Board of Directors has elected John Bishop as Chairman of the Board and named Cristina Kepner as Lead Independent Director, effective February 12, 2013 Briefing.com |
| 04:05PM | Cepheid Announces Board of Directors Changes PR Newswire |
| 12-Feb-13 01:58PM | Still Neutral on Cepheid Zacks |
| 04-Feb-13 04:12PM | CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 01-Feb-13 02:08PM | Abaxis Surpasses Estimates in 3Q Zacks |
| 31-Jan-13 04:05PM | Cepheid to Webcast Upcoming Financial Presentations PR Newswire |
| 28-Jan-13 08:08AM | All-Front Easy Beat for Covance Zacks |
| 27-Jan-13 09:21AM | New Star Analyst Rankings for CEPHEID StarMine |
| 25-Jan-13 10:23AM | Cepheid Under Pressure and 4 Stock Analyses Making Rounds at Wall St. Cheat Sheet +6.62% |
| 10:18AM | Cepheid Turns to Profit in 4Q Zacks |
| 09:19AM | New Star Analyst Rankings for CEPHEID StarMine |
| 04:00AM | Cepheid Stock Upgraded (CPHD) at TheStreet |
| 24-Jan-13 11:30PM | Cepheid's CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 04:13PM | InPlay: Cepheid beats by $0.09, reports revs in-line; guides FY13 EPS below consensus, revs below consensus Briefing.com |
| 04:11PM | CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:05PM | Cepheid Reports Fourth Quarter And Full Year 2012 Results PR Newswire |
| 22-Jan-13 02:17PM | VeriFone Performance Remains Strong and 4 Must-See Stock Analyses at Wall St. Cheat Sheet |
| 08:54AM | Week Ahead Market Report: 1/22/13 at Forbes |
| 16-Jan-13 04:11PM | CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers, Other Events EDGAR Online |
| 02:18PM | FDA Categorizes Cepheid's New Test Zacks |
| 12:53PM | Wedge Down Equals Thumbs Up at Investopedia |
| 15-Jan-13 07:25AM | InPlay from Briefing.com Briefing.com |
| 07:03AM | InPlay: Cepheid announces Chlamydia and N. gonorrhoeae test categorized 'Moderate Complexity' by FDA Briefing.com |
| 07:00AM | Cepheid Announces Chlamydia and N. gonorrhoeae Test Categorized 'Moderate Complexity' by FDA PR Newswire |
| 10-Jan-13 02:08PM | Cepheid Unveils Prelim 4Q Results Zacks |
| 08-Jan-13 04:55PM | Cepheid shares rise on 4Q guidance AP |
| 02:26PM | Strong Flu Could Boost Some Health Care Profits at CNBC |
| 12:43PM | Why Cepheid Shares Popped at Motley Fool |
| 10:20AM | Cepheid rises after saying Q4 EPS should beat prior guidance at theflyonthewall.com |
| 08:47AM | CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 08:30AM | Cepheid Announces Update On Xpert® Test Availability PR Newswire |
| 04-Jan-13 11:16AM | Cepheid Pullback Viewed as Overdone and 4 Stock Analyses to Know Now at Wall St. Cheat Sheet |
| 03-Jan-13 12:31PM | Ross Among the Nasdaq's Biggest Movers on January 3, 2013 at Investopedia |
| 12:31PM | Technology Stocks, Including Mindray Medical International Ltd, Making Big Moves on January 3, 2013 at Investopedia |
| 02-Jan-13 11:57AM | Medtech News Over The Christmas Period at Seeking Alpha |
| 30-Dec-12 11:13AM | Cepheid Wins FDA Clearance for Xpert CT/NG, TranS1 Settles with DOJ: Healthcare Business Recap at Wall St. Cheat Sheet |
|
|
| Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. Cepheid also provides GeneXpert Infinity System for high volume testing. The company offers tests for the GeneXpert and the SmartCycler systems in the areas of healthcare associated infections, critical infectious disease, sexual health, women's health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and through third-party distributors worldwide. It has collaboration agreements with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was founded in 1996 and is headquartered in Sunnyvale, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| FLOM KERRY | EVP, Regulatory Affairs | May 13 | Option Exercise | 13.25 | 6,250 | 82,788 | 26,832 | May 14 04:15 PM | | FLOM KERRY | EVP, Regulatory Affairs | May 13 | Sale | 39.76 | 6,832 | 271,646 | 20,000 | May 14 04:15 PM | | Reyes Humberto | Executive VP, COO | Apr 29 | Option Exercise | 0.00 | 339 | 0 | 16,885 | May 01 05:11 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Apr 29 | Option Exercise | 0.00 | 313 | 0 | 8,892 | May 01 05:12 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Apr 29 | Option Exercise | 0.00 | 339 | 0 | 4,813 | May 01 05:10 PM | | Miller Andrew | EVP, CFO | Apr 29 | Option Exercise | 0.00 | 1,250 | 0 | 12,938 | May 01 05:09 PM | | BISHOP JOHN L | Chairman of the Board and CEO | Apr 29 | Option Exercise | 0.00 | 1,250 | 0 | 34,066 | May 01 05:07 PM | | STEELE GLENN JR MD PHD | Director | Apr 26 | Option Exercise | 0.00 | 700 | 0 | 4,583 | Apr 30 04:05 PM | | Miller Andrew | EVP, CFO | Apr 25 | Option Exercise | 0.00 | 250 | 0 | 11,782 | Apr 25 08:37 PM | | FLOM KERRY | EVP, Regulatory Affairs | Apr 25 | Option Exercise | 0.00 | 237 | 0 | 20,659 | Apr 25 08:34 PM | | Reyes Humberto | Executive VP, COO | Apr 25 | Option Exercise | 0.00 | 313 | 0 | 16,664 | Apr 25 08:40 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Apr 25 | Option Exercise | 0.00 | 302 | 0 | 4,588 | Apr 25 08:39 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Apr 25 | Option Exercise | 0.00 | 250 | 0 | 8,710 | Apr 25 08:41 PM | | BISHOP JOHN L | Chairman of the Board and CEO | Apr 25 | Option Exercise | 0.00 | 1,563 | 0 | 33,632 | Apr 25 08:32 PM | | STEELE GLENN JR MD PHD | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 3,883 | Apr 25 08:42 PM | | BISHOP JOHN L | Chairman of the Board and CEO | Apr 24 | Option Exercise | 0.00 | 4,250 | 0 | 34,287 | Apr 25 08:32 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Apr 24 | Option Exercise | 0.00 | 625 | 0 | 8,787 | Apr 25 08:41 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Apr 24 | Option Exercise | 0.00 | 1,355 | 0 | 4,796 | Apr 25 08:39 PM | | Reyes Humberto | Executive VP, COO | Apr 24 | Option Exercise | 0.00 | 1,355 | 0 | 16,861 | Apr 25 08:40 PM | | RENTON HOLLINGS | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 8,650 | Apr 25 08:39 PM | | MORTON DEAN O | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 15,650 | Apr 25 08:38 PM | | GUTSHALL THOMAS L | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 90,175 | Apr 25 08:35 PM | | EASTON ROBERT J | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 78,782 | Apr 25 08:34 PM | | FLOM KERRY | EVP, Regulatory Affairs | Apr 24 | Option Exercise | 0.00 | 625 | 0 | 20,625 | Apr 25 08:34 PM | | Brown Thomas D | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 26,338 | Apr 25 08:33 PM | | Miller Andrew | EVP, CFO | Apr 24 | Option Exercise | 0.00 | 1,355 | 0 | 12,042 | Apr 25 08:37 PM | | KEPNER CRISTINA | Director | Apr 24 | Option Exercise | 0.00 | 1,050 | 0 | 225,779 | Apr 25 08:36 PM | | GUTSHALL THOMAS L | Director | Apr 24 | Sale | 38.00 | 3,000 | 113,999 | 397,800 | Apr 25 08:35 PM | | BISHOP JOHN L | Chairman of the Board and CEO | Apr 22 | Option Exercise | 9.18 | 134,799 | 1,237,455 | 164,836 | Apr 23 04:06 PM | | BISHOP JOHN L | Chairman of the Board and CEO | Apr 22 | Sale | 37.51 | 134,799 | 5,056,027 | 30,037 | Apr 23 04:06 PM | | Miller Andrew | EVP, CFO | Apr 03 | Option Exercise | 0.00 | 625 | 0 | 10,922 | Apr 04 08:32 PM | | GUTSHALL THOMAS L | Director | Feb 25 | Sale | 36.42 | 3,000 | 109,273 | 682,300 | Feb 25 04:13 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Feb 22 | Option Exercise | 7.38 | 15,000 | 110,700 | 18,441 | Feb 25 04:13 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Feb 22 | Sale | 36.13 | 15,000 | 541,994 | 3,441 | Feb 25 04:13 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Feb 21 | Option Exercise | 4.30 | 10 | 43 | 8,172 | Feb 25 04:12 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Feb 21 | Sale | 35.53 | 10 | 355 | 8,162 | Feb 25 04:12 PM | | Brown Thomas D | Director | Feb 08 | Option Exercise | 9.18 | 10,000 | 91,800 | 30,358 | Feb 12 04:05 PM | | EASTON ROBERT J | Director | Feb 08 | Option Exercise | 9.18 | 12,500 | 114,750 | 89,842 | Feb 12 04:06 PM | | Brown Thomas D | Director | Feb 08 | Sale | 36.07 | 3,054 | 110,156 | 24,758 | Feb 12 04:05 PM | | EASTON ROBERT J | Director | Feb 08 | Sale | 36.05 | 12,500 | 450,675 | 77,342 | Feb 12 04:06 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Feb 04 | Option Exercise | 9.11 | 38,400 | 349,824 | 46,562 | Feb 06 04:14 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Feb 04 | Sale | 36.20 | 38,400 | 1,390,222 | 8,162 | Feb 06 04:14 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Jan 29 | Option Exercise | 0.00 | 312 | 0 | 7,613 | Jan 30 04:14 PM | | Reyes Humberto | Executive VP, COO | Jan 29 | Option Exercise | 0.00 | 338 | 0 | 14,926 | Jan 30 04:13 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Jan 29 | Option Exercise | 0.00 | 338 | 0 | 3,508 | Jan 30 04:12 PM | | Miller Andrew | EVP, CFO | Jan 29 | Option Exercise | 0.00 | 1,250 | 0 | 10,756 | Jan 30 04:11 PM | | BISHOP JOHN L | CEO | Jan 29 | Option Exercise | 0.00 | 1,250 | 0 | 30,409 | Jan 30 04:11 PM | | FLOM KERRY | EVP, Regulatory Affairs | Jan 28 | Sale | 37.31 | 147 | 5,485 | 20,000 | Jan 30 04:10 PM | | FLOM KERRY | EVP, Regulatory Affairs | Jan 25 | Option Exercise | 30.33 | 6,487 | 196,781 | 26,250 | Jan 28 04:09 PM | | BISHOP JOHN L | CEO | Jan 25 | Option Exercise | 0.00 | 1,562 | 0 | 29,844 | Jan 28 04:08 PM | | Miller Andrew | EVP, CFO | Jan 25 | Option Exercise | 0.00 | 250 | 0 | 9,598 | Jan 28 04:10 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Jan 25 | Option Exercise | 0.00 | 302 | 0 | 3,303 | Jan 28 04:11 PM | | SMITH JOSEPH H | EVP, Bus Dev and GC | Jan 25 | Option Exercise | 0.00 | 250 | 0 | 7,411 | Jan 28 04:12 PM | | Reyes Humberto | Executive VP, COO | Jan 25 | Option Exercise | 0.00 | 312 | 0 | 14,725 | Jan 28 04:11 PM | | FLOM KERRY | EVP, Regulatory Affairs | Jan 25 | Sale | 38.00 | 6,250 | 237,500 | 20,000 | Jan 28 04:09 PM | | GUTSHALL THOMAS L | Director | Jan 24 | Sale | 35.20 | 3,000 | 105,599 | 685,300 | Jan 28 04:08 PM | | Miller Andrew | EVP, CFO | Jan 03 | Option Exercise | 0.00 | 2,500 | 0 | 10,520 | Jan 07 04:08 PM | | Enns Russell | Sr. VP, Regulatory | Dec 31 | Option Exercise | 0.00 | 4,125 | 0 | 6,528 | Jan 03 04:11 PM | | GUTSHALL THOMAS L | Director | Dec 24 | Sale | 33.06 | 3,000 | 99,193 | 688,300 | Dec 27 04:07 PM | | KEPNER CRISTINA | Director | Dec 18 | Option Exercise | 10.16 | 20,000 | 203,250 | 224,156 | Dec 19 04:06 PM | | KEPNER CRISTINA | Director | Dec 17 | Option Exercise | 7.69 | 20,000 | 153,750 | 204,156 | Dec 19 04:06 PM | | GUTSHALL THOMAS L | Director | Nov 27 | Option Exercise | 10.83 | 20,222 | 219,013 | 109,347 | Nov 29 04:26 PM | | GUTSHALL THOMAS L | Director | Nov 27 | Sale | 31.80 | 20,222 | 643,149 | 89,125 | Nov 29 04:26 PM | | GUTSHALL THOMAS L | Director | Nov 26 | Option Exercise | 9.18 | 4,778 | 43,862 | 93,903 | Nov 27 04:10 PM | | GUTSHALL THOMAS L | Director | Nov 26 | Sale | 32.00 | 4,778 | 152,898 | 89,125 | Nov 27 04:10 PM | | GUTSHALL THOMAS L | Director | Nov 26 | Sale | 31.83 | 3,000 | 95,494 | 691,300 | Nov 27 04:10 PM | | SMITH JOSEPH H | SVP, Bus Dev and GC | Oct 29 | Option Exercise | 0.00 | 313 | 0 | 7,308 | Oct 31 04:32 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Oct 29 | Option Exercise | 0.00 | 339 | 0 | 3,160 | Oct 31 04:31 PM | | Reyes Humberto | Executive VP, COO | Oct 29 | Option Exercise | 0.00 | 339 | 0 | 14,572 | Oct 31 04:31 PM | | Miller Andrew | EVP, CFO | Oct 29 | Option Exercise | 0.00 | 1,250 | 0 | 8,604 | Oct 31 04:30 PM | | BISHOP JOHN L | CEO | Oct 29 | Option Exercise | 0.00 | 1,250 | 0 | 28,866 | Oct 31 04:28 PM | | Enns Russell | Sr. VP, Regulatory | Oct 29 | Option Exercise | 0.00 | 271 | 0 | 2,530 | Oct 31 04:29 PM | | ARNOLD NICOLAAS | EVP, Worldwide Comm'l Ops | Oct 29 | Option Exercise | 0.00 | 344 | 0 | 3,589 | Oct 31 04:27 PM | | SMITH JOSEPH H | SVP, Bus Dev and GC | Oct 25 | Option Exercise | 0.00 | 250 | 0 | 7,112 | Oct 29 04:08 PM | | SMITH JOSEPH H | SVP, Bus Dev and GC | Oct 25 | Option Exercise | 0.00 | 250 | 0 | 7,112 | Oct 29 04:09 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Oct 25 | Option Exercise | 0.00 | 302 | 0 | 2,962 | Oct 29 04:07 PM | | Reyes Humberto | Executive VP, COO | Oct 25 | Option Exercise | 0.00 | 313 | 0 | 14,380 | Oct 29 04:08 PM | | Enns Russell | Sr. VP, Regulatory | Oct 25 | Option Exercise | 0.00 | 250 | 0 | 2,376 | Oct 29 04:06 PM | | Enns Russell | Sr. VP, Regulatory | Oct 25 | Option Exercise | 0.00 | 250 | 0 | 2,376 | Oct 29 04:07 PM | | ARNOLD NICOLAAS | EVP, Worldwide Comm'l Ops | Oct 25 | Option Exercise | 0.00 | 250 | 0 | 3,362 | Oct 29 04:05 PM | | BISHOP JOHN L | CEO | Oct 25 | Option Exercise | 0.00 | 1,563 | 0 | 28,346 | Oct 29 04:06 PM | | Miller Andrew | EVP, CFO | Oct 25 | Option Exercise | 0.00 | 250 | 0 | 7,471 | Oct 31 04:30 PM | | GUTSHALL THOMAS L | Director | Oct 24 | Sale | 31.50 | 3,000 | 94,502 | 694,300 | Oct 25 04:05 PM | | EASTON ROBERT J | Director | Oct 22 | Option Exercise | 7.35 | 7,500 | 55,125 | 84,360 | Oct 23 04:06 PM | | EASTON ROBERT J | Director | Oct 22 | Sale | 31.63 | 7,500 | 237,192 | 76,860 | Oct 23 04:06 PM | | GUTSHALL THOMAS L | Director | Sep 24 | Sale | 40.13 | 3,000 | 120,404 | 697,300 | Sep 25 04:05 PM | | ARNOLD NICOLAAS | EVP, Worldwide Comm'l Ops | Aug 30 | Option Exercise | 14.93 | 15,000 | 223,950 | 18,112 | Aug 30 08:31 PM | | EASTON ROBERT J | Director | Aug 30 | Option Exercise | 5.20 | 7,500 | 39,000 | 84,360 | Aug 30 08:32 PM | | ARNOLD NICOLAAS | EVP, Worldwide Comm'l Ops | Aug 30 | Sale | 37.12 | 15,000 | 556,784 | 3,112 | Aug 30 08:31 PM | | GUTSHALL THOMAS L | Director | Aug 30 | Sale | 37.41 | 40,000 | 1,496,564 | 700,300 | Aug 30 08:32 PM | | EASTON ROBERT J | Director | Aug 30 | Sale | 36.82 | 7,500 | 276,150 | 76,860 | Aug 30 08:32 PM | | GUTSHALL THOMAS L | Director | Aug 24 | Sale | 35.97 | 3,000 | 107,910 | 740,300 | Aug 27 04:05 PM | | SMITH JOSEPH H | SVP, Bus Dev and GC | Jul 29 | Option Exercise | 0.00 | 312 | 0 | 6,917 | Jul 31 04:09 PM | | Miller Andrew | EVP, CFO | Jul 29 | Option Exercise | 0.00 | 1,250 | 0 | 7,805 | Jul 31 04:07 PM | | PERSING DAVID H | Exec VP,Chief Med/Tech Officer | Jul 29 | Option Exercise | 0.00 | 338 | 0 | 2,736 | Jul 31 04:08 PM | | Reyes Humberto | Executive VP, COO | Jul 29 | Option Exercise | 0.00 | 338 | 0 | 14,191 | Jul 31 04:08 PM | | Enns Russell | Sr. VP, Regulatory | Jul 29 | Option Exercise | 0.00 | 270 | 0 | 2,253 | Jul 31 04:07 PM | | BISHOP JOHN L | CEO | Jul 29 | Option Exercise | 0.00 | 1,250 | 0 | 27,262 | Jul 31 04:06 PM | | ARNOLD NICOLAAS | EVP, Worldwide Comm'l Ops | Jul 29 | Option Exercise | 0.00 | 343 | 0 | 2,695 | Jul 31 04:06 PM | | ARNOLD NICOLAAS | EVP, Worldwide Comm'l Ops | Jul 25 | Option Exercise | 0.00 | 250 | 0 | 2,469 | Jul 26 04:06 PM |
|
|
|
|
|
|
